Cyclophosphamide Patent Expiration
Cyclophosphamide was first introduced by Baxter Healthcare Corp
Cyclophosphamide Patents
Given below is the list of patents protecting Cyclophosphamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cyclophosphamide | US10993952 | Stable ready to use cyclophosphamide liquid formulations | Feb 15, 2036 | Dr Reddys |
| Cyclophosphamide | US11382923 | Stable liquid formulations of cyclophosphamide and processes to prepare the same | Dec 01, 2035 | Avyxa Holdings |
| Cyclophosphamide | US10849916 | Stable liquid formulations of cyclophosphamide and its impurities | Jul 13, 2035 | Avyxa Holdings |
| Cyclophosphamide | US9662342 | Formulations of cyclophosphamide liquid concentrate | Jun 26, 2035 | Eugia Pharma Speclts |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cyclophosphamide's patents.
Latest Legal Activities on Cyclophosphamide's Patents
Given below is the list recent legal activities going on the following patents of Cyclophosphamide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 May, 2024 | US10849916 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10993952(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical
| 12 Jul, 2022 | US11382923 |
| Recordation of Patent Grant Mailed Critical
| 12 Jul, 2022 | US11382923 |
| Email Notification Critical
| 23 Jun, 2022 | US11382923 |
| Issue Notification Mailed Critical
| 22 Jun, 2022 | US11382923 |
| Application Is Considered Ready for Issue Critical
| 08 Jun, 2022 | US11382923 |
| Dispatch to FDC | 08 Jun, 2022 | US11382923 |
| Issue Fee Payment Received Critical
| 06 Jun, 2022 | US11382923 |
| Issue Fee Payment Verified Critical
| 06 Jun, 2022 | US11382923 |
Cyclophosphamide's Family Patents
